Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo

@article{MeierDavis2012ComparisonOO,
  title={Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo},
  author={S. R. Meier-Davis and Kevin Dines and Fatima M Arjmand and R. Hamlin and Betsy Huang and Jainye Wen and Chad D Christianson and J. Shudo and T. Nagata},
  journal={Cutaneous and Ocular Toxicology},
  year={2012},
  volume={31},
  pages={312 - 317}
}
  • S. R. Meier-Davis, Kevin Dines, +6 authors T. Nagata
  • Published 2012
  • Medicine
  • Cutaneous and Ocular Toxicology
  • Background/Aims: Transdermal patch administration results in a locally high concentration of drug that induce local toxicity, including tumorogenicity. As a worst-case scenario for consequences of repeated application on neoplastic growth, the melanin-binding drug, rasagiline, was used in a transdermal formulation applied directly to a human-derived melanoma to determine the effects on tumor growth. Materials and Methods: Rasagiline mesylate was administered either orally or transdermally to… CONTINUE READING
    4 Citations

    References

    SHOWING 1-10 OF 21 REFERENCES
    Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma.
    • 40
    Tyrosinase activated melanoma prodrugs.
    • 32
    Reactive oxygen species: an Achilles’ heel of melanoma?
    • 82
    Skin cancer and Parkinson's disease
    • 37
    • PDF
    Long-Term Efficacy of Rasagiline in Early Parkinson's Disease
    • 26
    Vertebrate melanophores as potential model for drug discovery and development: A review
    • 26
    • PDF
    Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
    • 129